FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare

Free Newsletter

Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today!

About | Sample | Privacy

Study: Antipsychotics hike stroke risk for all

Tools

The risk of stroke among patients taking antipsychotics may be more widespread than we thought. British researchers are saying that the risk accompanies all antipsychotics--not just the newer "atypicals" like Abilify and Zyprexa, as once thought. And all patients on these drugs have a greater risk--not just those with dementia, the researchers found.

The study looked at 6,790 patients with an average age of 80. It's true that the stroke risk was slightly higher for people taking atypicals versus the older antipsychotics such as Thorazine and Haldol. And the risk of stroke was also much greater in dementia patients (their risk actually tripled). But even patients without dementia saw their stroke risk magnified by 40 percent.

Echoing an FDA warning on the atypical meds, researchers said that patients with dementia shouldn't be taking these drugs--or their older brethren, either. Alzheimer's expert Dr. Sam Gandy said the new study "elevates the concern about risks of antipsychotics to a whole new level." The FDA might want to investigate, he said.

- read the story in the Washington Post
- check out the BBC article

Related Articles:
Painkillers little help against dementia
Big pharma sees big payback for Alzheimer's research
Alzheimer's vax eliminated plaque, not dementia
Genetic engineering ‘vacuums' Alzheimer plaque

More stories about Antipsychotic Drugs   Dementia   Alzheimer's  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 17 + 8?
To combat spam, please solve the math question above.